Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Blood Rev. 2010 Feb 11;24(2):69–82. doi: 10.1016/j.blre.2010.01.001

Table 4.

Response rates of single Lenalidomide in NHL.

Study Status Regimens Patients Results (%)
ORR CR/CRu
Wiernik et al. [65] Phase II 25 mg QD, 21 of 28 days Relapsed/refractory aggressive NHL (n = 50) 35 6
Zinzani et al. [66] Phase II 25 mg QD, 21 of 28 days Relapsed/refractory indolent NHL (n = 39) 41 13
Chanan-Khan et al. [68] Phase II 25 mg QD, 21 of 28 days Relapsed/refractory CLL (n = 45) 47 9
Ferrajoli et al. [69] Phase II 10 mg QD, escalated to maximum of 25 mg QD Relapsed/refractory CLL (n = 44) 32 7
Chen et al. [70] Phase I 2.5 mg QD, escalated to 10 mg QD Untreated CLL (n = 25) 65 0
Ferrajoli et al. [71] Phase II 5 mg QD, escalated to maximum of 25 mg QD Untreated CLL (n = 35) 54 0

CLL – chronic lymphocytic leukemia; CR – complete response; CRu – complete response unconfirmed; FL – follicular lymphoma; MAb – monoclonal antibody; NHL – non-Hodgkin lymphoma; oRr – overall response rate.